TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid
Leuven (BELGIUM), Madrid (SPAIN) – January 29, 2013 – TiGenix (Euronext Brussels:TIG), a leader in the field of cell therapy, announced today that further to the cGMPinspection by the Spanish health authorities it has successfully renewed its manufacturingauthorization for stem cell products at its manufacturing facility in Madrid, Spain.
“The GMP facility in Madrid performs a vital function within our organization bymanufacturing high-quality, clinical grade allogeneic stem cell products to fuel our keyclinical programs,” said Wilfried Dalemans, CTO of TiGenix. “It is an important steppingstone before we can move to commercial manufacturing at our state-of-the-art, central GMPmanufacturing site in Sittard-Geleen, the Netherlands. Our strong cell therapy manufacturing capabilities place us at the forefront of the cell therapy industry.”
For more information:
Officer Chief Financial Officer
Director Investor & Media Relations
+32 16 39 60 97
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.
This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix’ control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix’ expectations with regard thereto, or any change in events, conditions or circumstances on which